New Jersey headquartered Amicus Therapeutics Inc.'s stock finished Thursday's session 0.33% higher at $6.13 with a total trading volume of 3.04 million shares. The Company's shares have advanced 7.54% in the past month and 23.34% since the start of this year. The stock is trading 10.40% above its 50-day moving average. Additionally, shares of Amicus Therapeutics, which focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases, have a Relative Strength Index (RSI) of 61.82.
On January 09th, 2017, Amicus Therapeutics announced that for full year 2017 it is focusing on five key strategic priorities: 1) advancing the international Galafold launch; 2) completing its regulatory submission for migalastat in Japan; 3) establishing the Company's novel Pompe treatment paradigm ATB200/AT2221 as a highly differentiated therapy; 4) successfully completing its Phase-3 clinical study in patients with epidermolysis bullosa; and 5) maintaining its financing strength. The Company expects full-year 2017 net operating cash flow of between $175 million to $200 million.
On January 24th, 2017, research firm Robert W. Baird upgraded the Company's stock rating from 'Neutral' to 'Outperform' while revising its previous target price from $7 a share to $10 a share. FOLD complete research report is just a click away and free at:
On Thursday, shares in North Carolina headquartered Cempra Inc. recorded a trading volume of 1.69 million shares. The stock ended the session 5.17% higher at $3.05. The Company's shares have advanced 8.93% on an YTD basis. The stock is trading 36.27% below its 50-day moving average. Moreover, shares of Cempra, which focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America, have an RSI of 33.51.
On December 29th, 2016, Cempra announced that it has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) relating to its new drug applications (NDAs) for oral and intravenous solithromycin for the treatment of community-acquired bacterial pneumonia in adults. The CRL states that the FDA cannot approve the NDAs in their present form and notes that additional clinical safety information and the satisfactory resolution of manufacturing facility inspection deficiencies are required before the NDAs may be approved. The complimentary report on CEMP can be downloaded at:
Shares in New York headquartered Ophthotech Corp. closed the day 1.59% lower at $4.32 with a total trading volume of 1.64 million shares. The stock is trading 60.14% below its 50-day moving average. Shares of the Company, which develops novel therapeutics to treat diseases of the back of the eye, have an RSI of 8.70.
On February 01st, 2017, Ophthotech announced that it has initiated a plan to review its strategic alternatives in order to maximize shareholder value. Without limiting any option, the principal focus of this plan, based on the Company's deep expertise and experience in ophthalmology, is to actively explore obtaining rights to additional products, product candidates and technologies to treat ophthalmic diseases, particularly those of the back of the eye. As part of implementing the strategic plan, the Company announced that Glenn P. Sblendorio will assume the role of President, effective immediately. Sign up for your complimentary research report on OPHT at:
At the close of trading on Thursday, shares in Massachusetts headquartered Sarepta Therapeutics Inc. finished 0.27% higher at $29.34. The stock recorded a trading volume of 2.08 million shares. The Company's shares have advanced 6.96% on an YTD basis. The stock is trading below its 200-day moving average by 4.23%. Furthermore, shares of Sarepta Therapeutics, which focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases, have an RSI of 42.88.
On January 31st, 2017, Sarepta Therapeutics announced that it has been granted equity awards that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2014 Employment Commencement Incentive Plan. The Company's employees received, in the aggregate, options to purchase 101,325 shares of Sarepta's common stock. The options have an exercise price of $31.06 per share, which is equal to the closing price of Sarepta's common stock on January 31st, 2017. Get free access to your research report on SRPT at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA